Assessment of irradiated brain metastases using dynamic contrast-enhanced magnetic resonance imaging

Almeida-Freitas, Daniela B.; Pinho, Marco da Cunha; Otaduy, Maria C. G.; Braga, Henrique Faria; Meira-Freitas, Daniel; Leite, Cláudia da Costa

doi:10.1007/s00234-014-1344-0

Cited by 14 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one study, lower Ktrans and lower relative CBF (rCBF) at 1 week after treatment correlated with responders, whereas higher rCBF and rCBV at 4 weeks were associated with therapy benefit (Jakubovic et al, 2014). Another study also analyzed Ktrans data and found that even a small increase in Ktrans at 4–8 weeks after SRS was associated with tumor progression (Almeida-Freitas et al, 2014), similar to a prior analysis that found that increased CBV at 6 and 12 weeks is associated with worse outcome (Fig. 7.5) (Essig et al, 2003).…”

Section: Early Response Markerssupporting

confidence: 64%

Brain metastases: neuroimaging

Pope

2018

Handbook of Clinical Neurology

155

130

View full text Add to dashboard Cite

Magnetic resonance imaging (MRI) is the cornerstone for evaluating patients with brain masses such as primary and metastatic tumors. Important challenges in effectively detecting and diagnosing brain metastases and in accurately characterizing their subsequent response to treatment remain. These difficulties include discriminating metastases from potential mimics such as primary brain tumors and infection, detecting small metastases, and differentiating treatment response from tumor recurrence and progression. Optimal patient management could be benefited by improved and well-validated prognostic and predictive imaging markers, as well as early response markers to identify successful treatment prior to changes in tumor size. To address these fundamental needs, newer MRI techniques including diffusion and perfusion imaging, MR spectroscopy, and positron emission tomography (PET) tracers beyond traditionally used 18-fluorodeoxyglucose are the subject of extensive ongoing investigations, with several promising avenues of added value already identified. These newer techniques provide a wealth of physiologic and metabolic information that may supplement standard MR evaluation, by providing the ability to monitor and characterize cellularity, angiogenesis, perfusion, pH, hypoxia, metabolite concentrations, and other critical features of malignancy. This chapter reviews standard and advanced imaging of brain metastases provided by computed tomography, MRI, and amino acid PET, focusing on potential biomarkers that can serve as problem-solving tools in the clinical management of patients with brain metastases.

show abstract

Section: Early Response Markerssupporting

confidence: 64%

Brain metastases: neuroimaging

Pope

2018

Handbook of Clinical Neurology

155

130

View full text Add to dashboard Cite

show abstract

“…For example, Almeida-Freitas et al studied a mixed-histology cohort of 26 patients with 34 BMs treated with SRS. 30 All patients were treated with SRS and then reimaged 4-8 weeks after therapy. The researchers found that an increase of 15% in K trans after SRS was significantly predictive of tumor progression.…”

Section: Discussionmentioning

confidence: 99%

Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery

Taunk

Shukla–Dave

et al. 2017

Neuro-Oncology

View full text Add to dashboard Cite

show abstract

“…Quite similarly, Cao et al 25 investigating the effect of radiation therapy on the blood-brain barrier permeability of primary brain tumours using dynamicenhanced MRI noted a gradual decrease of K trans as soon as 1 month after the treatment. More recently, Almeida-Freitas et al 26 reported a significant reduction in K trans values of cerebral metastasis 4-8 weeks after stereotactic radiosurgery. An increase of one or both parameters at the beginning of treatment should not be misinterpreted as increasing resistance.…”

Section: Discussionmentioning

confidence: 97%

Radiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours

Abramyuk

Hietschold²,

Appold³

et al. 2015

BJR

View full text Add to dashboard Cite

Cite this article as: Abramyuk A, Hietschold V, Appold S, von Kummer R, Abolmaali N. Radiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours. Br J Radiol 2015;88:20140412. FULL PAPERRadiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours 1 A ABRAMYUK,

show abstract

Assessment of irradiated brain metastases using dynamic contrast-enhanced magnetic resonance imaging

Abstract: SRS was associated with a reduction of K trans values of the cerebral metastases in the early post-treatment period. Furthermore, K trans variation as assessed using DCE MRI may be helpful to predict midterm outcomes after SRS.

Cited by 14 publications

References 22 publications

Brain metastases: neuroimaging

Brain metastases: neuroimaging

Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery

Radiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours

Contact Info

Product

Resources

About